Drug Patents owned by Tersera

1. Drug name - PRIALT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9707270 TERSERA Method for administering ω-conopeptide Oct, 2024

(2 years from now)

US8653033 TERSERA Method for administering omega-conopeptide Oct, 2024

(2 years from now)

US8765680 TERSERA Method for administering omega-conopeptide Oct, 2024

(2 years from now)

Drugs and Companies using ZICONOTIDE ACETATE ingredient

Treatment: Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine; Analgesia; treatment of pain; Treatment of pain; analgesia

Dosage: INJECTABLE;INTRATHECAL

More Information on Dosage
Strength Dosage Availability
100MCG/1ML (100MCG/ML) INJECTABLE;INTRATHECAL Prescription
200MCG/2ML (100MCG/ML) INJECTABLE;INTRATHECAL Discontinued
500MCG/20ML (25MCG/ML) INJECTABLE;INTRATHECAL Prescription
500MCG/5ML (100MCG/ML) INJECTABLE;INTRATHECAL Prescription

2. Drug name - QMIIZ ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8545879 TERSERA Fast disintegrating compositions of meloxicam Aug, 2030

(7 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
7.5MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
15MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued

3. Drug name - VARUBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8178550 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy)-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor
Apr, 2027

(4 years from now)

US7049320 TERSERA NK1 antagonists
Aug, 2028

(5 years from now)

CN1606545A TERSERA Pyrrolidine And Piperidine Derivatives As Nk1 Antagonists
Nov, 2020

(1 year, 9 months ago)

CN1606545B TERSERA Pyrrolidine And Piperidine Derivatives As Nk1 Antagonist
Nov, 2020

(1 year, 9 months ago)

CN102276606B TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl] -8-Phenyl-1,7-Diaza-Spiro[4.5] Decan-2-One And Preparation Process Therefor
Mar, 2021

(1 year, 6 months ago)

CN102276606A TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl] -8-Phenyl-1,7-Diaza-Spiro[4.5] Decan-2-One And Preparation Process Therefor
Mar, 2021

(1 year, 6 months ago)

CN101437821B TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl] -8-Phenyl-1,7-Diaza-Spiro[4.5] Decan-2-One And Preparation Process Therefor
Mar, 2021

(1 year, 6 months ago)

CN101437821A TERSERA Hydrochloride Salts Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl)-Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Thereof
Mar, 2021

(1 year, 6 months ago)

IN200401329P4 TERSERA Pyrrolidine And Piperidine Derivatives Of General Formula I
Dec, 2022

(2 months from now)

IN218814B TERSERA Pyrrolidine And Piperidine Derivatives Of General Formula I
Dec, 2022

(2 months from now)

EP2004646B1 TERSERA Hydrochloride Salt Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor
Aug, 2020

(2 years ago)

EP2004646A2 TERSERA Hydrochloride Salt Of 8-[{1-(3,5-Bis-(Trifluoromethyl) Phenyl) -Ethoxy}-Methyl]-8-Phenyl-1,7-Diaza-Spiro[4.5]Decan-2-One And Preparation Process Therefor
Aug, 2020

(2 years ago)

EP1882686A2 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1882686A3 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1882686B1 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1463716A1 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

EP1463716B1 TERSERA Pyrrolidine And Piperidine Derivates As Nk1 Antagonists
Dec, 2022

(2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796299 TERSERA NK1 antagonists Dec, 2022

(2 months from now)

US8404702 TERSERA Pharmaceutical formulations:salts of 8-[1-3,5-bis-(trifluoromethyl)phenyl)-ethoxymethyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr, 2027

(4 years from now)

US7981905 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-Ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr, 2027

(4 years from now)

US7563801 TERSERA Pharmaceutical formulations: salts of 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same Apr, 2027

(4 years from now)

US8470842 TERSERA Hydrochloride salts of 8-[{1-(3,5-Bis-trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor Jan, 2029

(6 years from now)

US8361500 TERSERA Tablet formulations containing 8-[{1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one salts and tablets made therefrom Oct, 2029

(7 years from now)

US9101615 TERSERA Intravenous formulations of neurokinin-1 antagonists Jul, 2032

(9 years from now)

Drugs and Companies using ROLAPITANT HYDROCHLORIDE ingredient

Treatment: Prevention of delayed nausea and vomiting associated with emetogenic cancer chemotherapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 90MG BASE TABLET;ORAL Prescription

4. Drug name - XERMELO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7709493 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(5 years from now)

US7553840 TERSERA 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
Dec, 2027

(5 years from now)

US8193204 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use
Feb, 2031

(8 years from now)

CN101809018A TERSERA Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(6 years from now)

CN101809018B TERSERA (S)--2-Amino--3-(4-(2-Amino--6-((R) -1-(4-Chloro--2-(3-Methyl--1H-Pyrazol--1-Yl) Phenyl) -2, 2, 2-Trifluoro-Ethyoxyl)-Pyrimidin--4-Yl) Phenyl) Ethyl Propionate In Solid Form And Methods Of Use Thereof
Sep, 2028

(6 years from now)

IN200903374P4 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

IN282661B TERSERA 4-Phenyl-6-(2,2,2- Trifluoro-1- Phenylethoxy) Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

IN201002222P1 TERSERA Solids Forms Of (S)-Ethyl 2-Amin0-3-(4-(2-Amino-6-(R)-1-(4-Chl0R0-2-0-Methyl-Ihpyrazol- 1-Yl) Phenyl)-2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(6 years from now)

IN281019B TERSERA Crystalline Forms Of Tryptophan Hydroxylase Inhibitor And Pharmceutically Acceptable Salts Thereof
Sep, 2028

(6 years from now)

EP3176159B1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2589600B1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2589600A1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP3176159A1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2091940B1 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2091940B3 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2091940A2 TERSERA 4-Phenyl-6-(2,2,2-Trifluoro-1-Phenylethoxy)Pyrimidine-Based Compounds And Methods Of Their Use
Dec, 2027

(5 years from now)

EP2203444B1 TERSERA Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(6 years from now)

EP2203444A1 TERSERA Solids Forms Of ( S) -Ethyl 2-Amin0-3- (4- (2 -Amino- 6- ( (R) -1- (4-Chl0R0-2- O-Methyl-Ih-Pyrazol- 1-Yl) Phenyl) -2, 2, 2-Trifluorethoxy) -Pyrimidin-4-Yl) Phenyl) Propanoate
Sep, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7968559 TERSERA Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds Dec, 2027

(5 years from now)

US8653094 TERSERA Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use Dec, 2028

(6 years from now)

Drugs and Companies using TELOTRISTAT ETIPRATE ingredient

Treatment: The treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (ssa) therapy in adults inadequately controlled by ssa therapy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 250MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.